UBS Group’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-2,399,171
| Closed | -$31.4M | – | 10464 |
|
|
2025
Q4 | $31.4M | Buy |
2,399,171
+1,819,020
| +314% | +$21.7M | 0.01% | 2128 |
|
|
2025
Q3 | $4.22M | Sell |
580,151
-132,101
| -19% | -$894K | ﹤0.01% | 4220 |
|
|
2025
Q2 | $3.82M | Sell |
712,252
-531,224
| -43% | -$2.58M | ﹤0.01% | 4151 |
|
|
2025
Q1 | $6.64M | Sell |
1,243,476
-122,516
| -9% | -$857K | ﹤0.01% | 3494 |
|
|
2024
Q4 | $12.2M | Buy |
1,365,992
+1,305,907
| +2,173% | +$13.9M | ﹤0.01% | 2839 |
|
|
2024
Q3 | $662K | Sell |
60,085
-5,589
| -9% | -$62.1K | ﹤0.01% | 5004 |
|
|
2024
Q2 | $598K | Sell |
65,674
-60,374
| -48% | -$589K | ﹤0.01% | 4867 |
|
|
2024
Q1 | $1.77M | Buy |
126,048
+89,876
| +248% | +$1.12M | ﹤0.01% | 4068 |
|
|
2023
Q4 | $278K | Buy |
36,172
+23,245
| +180% | +$129K | ﹤0.01% | 5555 |
|
|
2023
Q3 | $96.4K | Sell |
12,927
-1,859
| -13% | -$15.9K | ﹤0.01% | 5856 |
|
|
2023
Q2 | $123K | Buy |
14,786
+12,114
| +453% | +$140K | ﹤0.01% | 5844 |
|
|
2023
Q1 | $35.5K | Buy |
2,672
+2,668
| +66,700% | +$36.1K | ﹤0.01% | 6680 |
|
|
2022
Q4 | $60 | Sell |
4
-3,258
| -100% | -$33.6K | ﹤0.01% | 10462 |
|
|
2022
Q3 | $29K | Buy |
3,262
+3,237
| +12,948% | +$21.7K | ﹤0.01% | 6908 |
|
|
2022
Q2 | $0 | Buy |
+25
| New | +$112 | ﹤0.01% | 10293 |
|
|
2022
Q1 | – | Sell |
-3,247
| Closed | -$18K | – | 10227 |
|
|
2021
Q4 | $18K | Buy |
3,247
+239
| +8% | +$1.57K | ﹤0.01% | 7959 |
|
|
2021
Q3 | $27K | Buy |
+3,008
| New | +$28.8K | ﹤0.01% | 6846 |
|
|
2021
Q2 | – | Sell |
-1,446
| Closed | -$25K | – | 9370 |
|
|
2021
Q1 | $25K | Buy |
1,446
+174
| +14% | +$3.14K | ﹤0.01% | 7163 |
|
|
2020
Q4 | $16K | Sell |
1,272
-4,223
| -77% | -$75.3K | ﹤0.01% | 7095 |
|
|
2020
Q3 | $204K | Sell |
5,495
-883
| -14% | -$35K | ﹤0.01% | 4787 |
|
|
2020
Q2 | $246K | Buy |
+6,378
| New | +$227K | ﹤0.01% | 4650 |
|
|
2019
Q3 | – | Sell |
-233
| Closed | -$11K | – | 7981 |
|
|
2019
Q2 | $11K | Buy |
233
+71
| +44% | +$3.22K | ﹤0.01% | 6994 |
|
|
2019
Q1 | $8K | Sell |
162
-353
| -69% | -$12K | ﹤0.01% | 6926 |
|
|
2018
Q4 | $14K | Buy |
+515
| New | +$19.5K | ﹤0.01% | 7028 |
|
|
2018
Q2 | – | Sell |
-97
| Closed | -$11K | – | 7966 |
|
|
2018
Q1 | $11K | Buy |
97
+61
| +169% | +$6.1K | ﹤0.01% | 6800 |
|
|
2017
Q4 | $3K | Sell |
36
-13
| -27% | -$1.53K | ﹤0.01% | 7520 |
|
|
2017
Q3 | $6K | Buy |
49
+44
| +880% | +$3.67K | ﹤0.01% | 7132 |
|
|
2017
Q2 | $0 | Buy |
+5
| New | +$416 | ﹤0.01% | 7649 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 7657 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 7708 |
|
|
2015
Q4 | – | Sell |
-362
| Closed | -$176K | – | 8326 |
|
|
2015
Q3 | $176K | Buy |
+362
| New | +$259K | ﹤0.01% | 4741 |
|
UBS Group's ATXS Position: Q1 2026 in Review
UBS Group sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 2,399,171 shares — an estimated $31.4M sold.
UBS Group first reported a position in ATXS in Q3 2015 and held it in 29 quarters. The position peaked at $31.4M in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- UBS Group reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- UBS Group sold 2,399,171 Astria Therapeutics shares in Q1 2026, an estimated $31.4M.
- UBS Group first reported a position in Astria Therapeutics in Q3 2015 and held it in 29 quarters.
- UBS Group's Astria Therapeutics position peaked at $31.4M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.